Stryker
Market Cap
US$77.5b
Last Updated
2020/09/21 05:56 UTC
Data Sources
Company Financials +
Executive Summary
Stryker Corporation operates as a medical technology company. More Details
Snowflake Analysis
Reasonable growth potential average dividend payer.
Similar Companies
Share Price & News
How has Stryker's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: SYK has not had significant price volatility in the past 3 months.
Market Performance
7 Day Return
0.4%
SYK
-0.8%
US Medical Equipment
-1.5%
US Market
1 Year Return
-6.3%
SYK
15.2%
US Medical Equipment
12.9%
US Market
Return vs Industry: SYK underperformed the US Medical Equipment industry which returned 14.8% over the past year.
Return vs Market: SYK underperformed the US Market which returned 12.8% over the past year.
Shareholder returns
| SYK | Industry | Market | |
|---|---|---|---|
| 7 Day | 0.4% | -0.8% | -1.5% |
| 30 Day | 9.3% | 1.2% | -1.8% |
| 90 Day | 10.5% | 10.8% | 6.6% |
| 1 Year | -5.1%-6.3% | 16.2%15.2% | 15.4%12.9% |
| 3 Year | 52.5%47.3% | 73.5%69.0% | 39.6%30.2% |
| 5 Year | 137.0%123.4% | 158.1%138.5% | 93.4%71.7% |
Price Volatility Vs. Market
How volatile is Stryker's share price compared to the market and industry in the last 5 years?
Simply Wall St News
1 month ago | Simply Wall St
How Is Stryker's (NYSE:SYK) CEO Compensated?3 months ago | Simply Wall St
Is Stryker's (NYSE:SYK) Share Price Gain Of 102% Well Earned?4 months ago | Simply Wall St
Why Stryker Corporation’s (NYSE:SYK) Return On Capital Employed Is ImpressiveValuation
Is Stryker undervalued compared to its fair value and its price relative to the market?
48.31x
Price to Earnings (PE) ratio
Share Price vs. Fair Value
Below Fair Value: SYK ($206.38) is trading above our estimate of fair value ($194.46)
Significantly Below Fair Value: SYK is trading above our estimate of fair value.
Price To Earnings Ratio
PE vs Industry: SYK is good value based on its PE Ratio (48.3x) compared to the US Medical Equipment industry average (50.5x).
PE vs Market: SYK is poor value based on its PE Ratio (48.3x) compared to the US market (18.2x).
Price to Earnings Growth Ratio
PEG Ratio: SYK is poor value based on its PEG Ratio (2.1x)
Price to Book Ratio
PB vs Industry: SYK is overvalued based on its PB Ratio (6.1x) compared to the US Medical Equipment industry average (4.1x).
Next Steps
Future Growth
How is Stryker forecast to perform in the next 1 to 3 years based on estimates from 26 analysts?
23.5%
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: SYK's forecast earnings growth (23.5% per year) is above the savings rate (2.2%).
Earnings vs Market: SYK's earnings (23.5% per year) are forecast to grow faster than the US market (23.1% per year).
High Growth Earnings: earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: SYK's revenue (9% per year) is forecast to grow slower than the US market (9.8% per year).
High Growth Revenue: SYK's revenue (9% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: SYK's Return on Equity is forecast to be high in 3 years time (21.9%)
Next Steps
Past Performance
How has Stryker performed over the past 5 years?
16.2%
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: SYK has a large one-off loss of $738.0M impacting its June 30 2020 financial results.
Growing Profit Margin: SYK's current net profit margins (11.4%) are lower than last year (25%).
Past Earnings Growth Analysis
Earnings Trend: SYK's earnings have grown by 16.2% per year over the past 5 years.
Accelerating Growth: SYK's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: SYK had negative earnings growth (-54.9%) over the past year, making it difficult to compare to the Medical Equipment industry average (-0.2%).
Return on Equity
High ROE: SYK's Return on Equity (12.6%) is considered low.
Next Steps
Financial Health
How is Stryker's financial position?
Financial Position Analysis
Short Term Liabilities: SYK's short term assets ($12.8B) exceed its short term liabilities ($4.4B).
Long Term Liabilities: SYK's short term assets ($12.8B) do not cover its long term liabilities ($14.3B).
Debt to Equity History and Analysis
Debt Level: SYK's debt to equity ratio (101.3%) is considered high.
Reducing Debt: SYK's debt to equity ratio has increased from 40.8% to 101.3% over the past 5 years.
Debt Coverage: SYK's debt is not well covered by operating cash flow (19.9%).
Interest Coverage: SYK's interest payments on its debt are well covered by EBIT (20.9x coverage).
Balance Sheet
Next Steps
Dividend
What is Stryker current dividend yield, its reliability and sustainability?
1.11%
Current Dividend Yield
Upcoming Dividend Payment
Dividend Yield vs Market
Notable Dividend: SYK's dividend (1.11%) isn’t notable compared to the bottom 25% of dividend payers in the US market (1.66%).
High Dividend: SYK's dividend (1.11%) is low compared to the top 25% of dividend payers in the US market (4.7%).
Stability and Growth of Payments
Stable Dividend: SYK's dividends per share have been stable in the past 10 years.
Growing Dividend: SYK's dividend payments have increased over the past 10 years.
Current Payout to Shareholders
Dividend Coverage: With its reasonable payout ratio (52.5%), SYK's dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: SYK's dividends in 3 years are forecast to be well covered by earnings (28.2% payout ratio).
Next Steps
Management
How experienced are the management team and are they aligned to shareholders interests?
2.4yrs
Average management tenure
CEO
Kevin Lobo (55 yo)
7.92yrs
Tenure
US$14,974,829
Compensation
Mr. Kevin A. Lobo, ACFE has been the Chief Executive Officer of Stryker Corporation since October 1, 2012. Mr. Lobo served as the President of Stryker from October 1, 2012 to August 1, 2018. He served as t ...
CEO Compensation Analysis
Compensation vs Market: Kevin's total compensation ($USD14.97M) is above average for companies of similar size in the US market ($USD11.35M).
Compensation vs Earnings: Kevin's compensation has been consistent with company performance over the past year.
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Chairman & CEO | 7.92yrs | US$14.97m | 0.019% $ 14.6m | |
| President & COO | 2.08yrs | US$7.11m | 0.050% $ 38.9m | |
| VP & CFO | 4.42yrs | US$4.38m | 0.0047% $ 3.7m | |
| VP & Chief Legal Officer | 1.42yrs | US$3.15m | 0.00078% $ 604.6k | |
| Group President of Global Quality & Operations | 2.42yrs | US$3.03m | 0.0012% $ 899.2k | |
| CTO and VP of Global R&D - Joint Replacement | no data | no data | no data | |
| Vice President of Investor Relations | 0.25yr | no data | no data | |
| Vice President of Compliance & Risk Management | 7.08yrs | no data | no data | |
| Vice President of Communications | 1.75yrs | no data | 0.0035% $ 2.7m | |
| VP & Chief Human Resources Officer | 4.67yrs | no data | 0.0034% $ 2.7m | |
| 0.25yr | no data | 0.00055% $ 426.3k | ||
| President of Neurovascular | 9.75yrs | no data | no data |
2.4yrs
Average Tenure
53.5yo
Average Age
Experienced Management: SYK's management team is considered experienced (2.4 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Chairman & CEO | 7.92yrs | US$14.97m | 0.019% $ 14.6m | |
| Independent Director | 0.33yr | no data | no data | |
| Director Emeritus | 2.33yrs | US$38.86k | no data | |
| Chairman Emeritus | no data | US$286.99k | 5.34% $ 4.1b | |
| Independent Director | 36.67yrs | US$290.11k | 6.05% $ 4.7b | |
| Independent Director | 3.08yrs | US$290.11k | 0.00069% $ 534.9k | |
| Independent Director | 10.25yrs | US$305.11k | 0.0059% $ 4.6m | |
| Independent Director | 11.17yrs | US$290.11k | 0.0063% $ 4.9m | |
| Lead Independent Director | 4yrs | US$325.11k | 0.0024% $ 1.9m | |
| Independent Director | 2.33yrs | US$300.08k | no data | |
| Independent Director | 2.33yrs | US$290.11k | 0.00053% $ 410.8k | |
| Independent Director | 6.83yrs | US$310.11k | 0.00051% $ 395.3k |
4.0yrs
Average Tenure
62.5yo
Average Age
Experienced Board: SYK's board of directors are considered experienced (4 years average tenure).
Ownership
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: SYK insiders have sold more shares than they have bought in the past 3 months.
Recent Insider Transactions
Ownership Breakdown
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Top Shareholders
Company Information
Stryker Corporation's company bio, employee growth, exchange listings and data sources
Key Information
- Name: Stryker Corporation
- Ticker: SYK
- Exchange: NYSE
- Founded: 1941
- Industry: Health Care Equipment
- Sector: Healthcare
- Market Cap: US$77.518b
- Shares outstanding: 375.61m
- Website: https://www.stryker.com
Number of Employees
Location
- Stryker Corporation
- 2825 Airview Boulevard
- Kalamazoo
- Michigan
- 49002
- United States
Listings
| Ticker | Exchange | Primary Security | Security Type | Country | Currency | Listed on |
|---|---|---|---|---|---|---|
| SYK | NYSE (New York Stock Exchange) | Yes | Common Stock | US | USD | Jan 1980 |
| SYK | DB (Deutsche Boerse AG) | Yes | Common Stock | DE | EUR | Jan 1980 |
| SYK | XTRA (XETRA Trading Platform) | Yes | Common Stock | DE | EUR | Jan 1980 |
| SYK | SWX (SIX Swiss Exchange) | Yes | Common Stock | CH | CHF | Jan 1980 |
| 0R2S | LSE (London Stock Exchange) | Yes | Common Stock | GB | USD | Jan 1980 |
| SYK * | BMV (Bolsa Mexicana de Valores) | Yes | Common Stock | MX | MXN | Jan 1980 |
| SYK | WBAG (Wiener Boerse AG) | Yes | Common Stock | AT | EUR | Jan 1980 |
| SYK | ETLX (Eurotlx) | Yes | Common Stock | IT | EUR | Jan 1980 |
| S1YK34 | BOVESPA (Bolsa de Valores de Sao Paulo) | BDR EACH 4 REPR 1 COM | BR | BRL | Jan 2020 |
Biography
Stryker Corporation operates as a medical technology company. The company operates through three segments: Orthopaedics, MedSurg, and Neurotechnology and Spine. The Orthopaedics segment provides implants f ...
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2020/09/21 05:56 |
| End of Day Share Price | 2020/09/18 00:00 |
| Earnings | 2020/06/30 |
| Annual Earnings | 2019/12/31 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.